Search

Your search keyword '"Ducreux M."' showing total 1,440 results
Start Over Author "Ducreux M."
1,440 results on '"Ducreux M."'

202. 2316 Efficacy and toxicity of second-line chemotherapy in patients with advanced oesophageal squamous cell carcinoma progressing after a first line of 5-fluorouracil and platinum-based therapy: An AGEO retrospective multicentric study

Author

Auzolle, C., primary, Dubreuil, O., additional, Pozet, A., additional, Coriat, R., additional, Dhooge, M., additional, Ducreux, M., additional, Mons, M., additional, Brieau, B., additional, Baumgaertner, I., additional, Gornet, J.M., additional, Li évre, A., additional, Locher, C., additional, Mary, F., additional, Bonnetain, F., additional, and Landi, B., additional

Published
2015
Full Text
View/download PDF

204. 2118 Quality of life (QoL) during second-line treatment with FOLFIRI +/- panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC)

Author

Sobrero, A.F., primary, Price, T.J., additional, Cervantes, A., additional, Ducreux, M., additional, Andre, T., additional, Lordick, F., additional, Punt, C.J., additional, Hechmati, G., additional, Demonty, G., additional, Koukakis, R., additional, and Peeters, M., additional

Published
2015
Full Text
View/download PDF

207. LBA-07 Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)

Author

Van Cutsem, E., primary, Atreya, C., additional, André, T., additional, Bendell, J., additional, Schellens, J., additional, Gordon, M., additional, McRee, A., additional, Yoshino, T., additional, Muro, K., additional, ODwyer, P., additional, Tabernero, J., additional, Middleton, G., additional, Ducreux, M., additional, van Geel, R., additional, Sidhu, R., additional, Greger, J., additional, Rangwala, F., additional, Liu, Y., additional, Wu, Y., additional, Mookerjee, B., additional, and Corcoran, R., additional

Published
2015
Full Text
View/download PDF

209. LBA-10 MODUL – A Multicentre Randomised Clinical Trial of Biomarker-Driven Therapy for the 1st-Line Maintenance Treatment of Metastatic Colorectal Cancer (mCRC): A Highly Adaptable Signal-Seeking Approach

Author

Arnold, D., primary, Schmoll, H-J., additional, de Gramont, A., additional, Ducreux, M., additional, Grothey, A., additional, O'Dwyer, P., additional, Tabernero, J., additional, Hermann, F., additional, Bendahmane, B., additional, Mancao, C., additional, and Van Cutsem, E., additional

Published
2015
Full Text
View/download PDF

210. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma

Author

Hadoux, J, primary, Malka, D, additional, Planchard, D, additional, Scoazec, J Y, additional, Caramella, C, additional, Guigay, J, additional, Boige, V, additional, Leboulleux, S, additional, Burtin, P, additional, Berdelou, A, additional, Loriot, Y, additional, Duvillard, P, additional, Chougnet, C N, additional, Déandréis, D, additional, Schlumberger, M, additional, Borget, I, additional, Ducreux, M, additional, and Baudin, E, additional

Published
2015
Full Text
View/download PDF

211. Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development

Author

Stahel, R., primary, Bogaerts, J., additional, Ciardiello, F., additional, de Ruysscher, D., additional, Dubsky, P., additional, Ducreux, M., additional, Finn, S., additional, Laurent-Puig, P., additional, Peters, S., additional, Piccart, M., additional, Smit, E., additional, Sotiriou, C., additional, Tejpar, S., additional, Van Cutsem, E., additional, and Tabernero, J., additional

Published
2015
Full Text
View/download PDF

212. Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

Author

Jung A.S., Strickland A., Van Cutsem E., Yu H., Sidhu R., Patterson S.D., Peeters M., Oliner K.S., Price T.J., Cervantes A., Sobrero A.F., Ducreux M., Hotko Y., Andre T., Chan E., Lordick F., Punt C.J.A., Wilson G., Ciuleanu T.E., Roman L., Jung A.S., Strickland A., Van Cutsem E., Yu H., Sidhu R., Patterson S.D., Peeters M., Oliner K.S., Price T.J., Cervantes A., Sobrero A.F., Ducreux M., Hotko Y., Andre T., Chan E., Lordick F., Punt C.J.A., Wilson G., Ciuleanu T.E., and Roman L.

Abstract

Background: Previously, extended RAS analysis from this study showed a trend toward improvements in HR on OS and PFS with pmab + FOLFIRI vs FOLFIRI in WT RAS group vs WT KRAS exon 2 group. Here we report updated RAS data and new analysis by BRAF status. Method(s): The primary objective was to assess the tx effect of pmab + FOLFIRI vs FOLFIRI on OS and PFS based on RAS/BRAF mutation status in the primary analysis population. Bidirectional Sanger sequencing was used to detect mutations in KRAS exons 3, 4and NRAS exons 2, 3, 4, and BRAF exon 15 in patients (pts) with known WT KRAS exon 2 mCRC. Result(s): Overall RAS/BRAF ascertainment rate was 85% (n=1014/1186). 18% of WT KRAS exon 2 pts harbored additional RAS mutations (n=107/597). The incidence of BRAF mutations was 8.3% (45/541). Efficacy is shown (table). Tx HR for pts with WT RAS was 0.81 (95% CI: 0.63, 1.03; P=0.08) for OS and 0.70 (95% CI: 0.54, 0.91; P=0.007) for PFS. Conclusion(s): Improvements continued to be observed in the tx effect of pmab + FOLFIRI vs FOLFIRI on OS and PFS in WT RAS group vs WT KRAS exon 2 group in this update. Pts with MT RAS mCRC are unlikely to benefit by the addition of pmab to FOLFIRI, similar to pts with MT KRAS exon 2 mCRC. BRAF mutations appear to be associated with reduced OS among pts without RAS mutations regardless of tx arm. These findings support RAS testing to determine potentially appropriate pts with mCRC for pmab tx.

Published
2014

213. Imagine a world without cancer

Author

Brücher, Bldm, Lyman, G, Van Hillegersberg, R, Pollock, Re, Lordick, F, Yang, H, Ushijima, T, Yeoh, K, Skricka, T, Polkowski, W, Wallner, G, Verwaal, V, Garofalo, A, D'Ugo, Domenico, Roviello, F, Steinau, H, Wallace, Tj, Daumer, M, Maihle, N, Reid, Tj, Ducreux, M, Kitagawa, Y, Knuth, A, Zilberstein, B, Steele, Sr, Jamall, Is, D'Ugo, Domenico (ORCID:0000-0001-6657-6318), Brücher, Bldm, Lyman, G, Van Hillegersberg, R, Pollock, Re, Lordick, F, Yang, H, Ushijima, T, Yeoh, K, Skricka, T, Polkowski, W, Wallner, G, Verwaal, V, Garofalo, A, D'Ugo, Domenico, Roviello, F, Steinau, H, Wallace, Tj, Daumer, M, Maihle, N, Reid, Tj, Ducreux, M, Kitagawa, Y, Knuth, A, Zilberstein, B, Steele, Sr, Jamall, Is, and D'Ugo, Domenico (ORCID:0000-0001-6657-6318)

Abstract

Since the "War on Cancer" was declared in 1971, the United States alone has expended some $300 billion on research, with a heavy focus on the role of genomics in anticancer therapy. Voluminous data have been collected and analyzed. However, in hindsight, any achievements made have not been realized in clinical practice in terms of overall survival or quality of life extended. This might be justified because cancer is not one disease but a conglomeration of multiple diseases, with widespread heterogeneity even within a single tumor type.

Published
2014

215. Thirteen-Month registration of patients with gastroenteropancreatic endocrine tumors in France

Author

Lecomte, Thierry, Lombard-Bohas, C., Mitry, E., O'Toole, D., Louvet, C., Pillon, D., Cadiot, G., Borson-Chazot, F., Aparicio, T., Ducreux, M., Etienne, Pl., Cacheux, W., Legoux, Jl., Seitz, Jf., Ruszniewski, P., Chayvialle, Ja., Rougier, P., Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011] (GICC UMR 6239 CNRS), and Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS)

Subjects
ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience

Published
2009

216. [Complete (R0) resection is the only valid prognostic factor in abdominoperineal resection for recurrent cancer of the anal canal (a consecutive series of 95 patients)]

Author

Rouquie, D, Lasser, P, Castaing, MARINE VERONIQUE, Boige, V, Goéré, D, Pignon, Jp, Ducreux, M, Elias, D, and Pocard, M.

Subjects
Male, Survival Rate, Time Factors, Rectal Neoplasms, Abdomen, Humans, Female, Middle Aged, Neoplasm Recurrence, Local, Perineum, Prognosis, Digestive System Surgical Procedures
Abstract

When radiation therapy fails to control cancer of the anal canal, the only therapeutic alternative is salvage abdomino-perineal resection (APR). Its role remains debatable since very few long-term survivals have been reported. No prognostic factors have yet been identified in the limited series of reported cases.95 APR's performed over a 20 year period are reviewed and analyzed.Median follow-up was 5.5 years. Only one prognostic factor was identified: an R0 resection (n=76) versus either R1 (n=9) or R2 (n=9) resection. Median survival for R0 APR was more than 10 years versus 1 year for R1 and R2 resections (p=0.001). There was no prognostic difference between salvage APR for disease progression (n=55) or for late recurrence (n=40). The sub-group of women45 years of age (n=5) had a particularly poor prognosis with no survivors beyond 2 years.When anal cancer recurs after radiation therapy, a salvage APR is indicated. If an R0 resection can be achieved, median survival is greater than 10 years. However, the justification for APR when only an R1 or R2 resection can be achieved is much less clear; in such cases there was no survival beyond 3 years.

Published
2008

217. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab

Author

Lièvre, A., J.B., Bachet, Boige, V., Cayre, A., Corre D., Le, Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., André, T., Bibeau, F., M.D., Diebold, Rougier, P., Ducreux, M., Tomasic, G., J.F., Emile, Penault-Llorca, F., Laurent-Puig, P., Matrice extracellulaire et dynamique cellulaire - UMR 7369 (MEDyC), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), and Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS)

Subjects
ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2008

220. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial

Author

Boige, V., J.L., Raoul, J.P., Pignon, Bouché, O., J.F., Blanc, Dahan, L., J.L., Jouve, Dupouy, N., Ducreux, M., Matrice extracellulaire et dynamique cellulaire - UMR 7369 (MEDyC), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), and Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Centre National de la Recherche Scientifique (CNRS)

Subjects
ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2007

225. Modul–A Multicentre Randomised Clinical Trial of Biomarker-Driven Therapy for the 1St-Line Maintenance Treatment of Metastatic Colorectal Cancer (Mcrc): a Signal-Seeking Approach

Author

Schmoll, H., primary, Arnold, D., additional, De Gramont, A., additional, Ducreux, M., additional, Grothey, A., additional, O'Dwyer, P.J., additional, Tabernero, J., additional, Bendahmane, B., additional, Hermann, F., additional, Ingold, C., additional, Mancao, C., additional, Osborne, S., additional, Statovci, I., additional, and Van Cutsem, E., additional

Published
2014
Full Text
View/download PDF

228. KRAS/NRAS and BRAF Mutations in the 20050181 Study of Panitumumab + FOLFIRI for the 2ND-Line Treatment of Metastatic Colorectal Cancer: Updated Analysis

Author

Peeters, M., primary, Oliner, K., additional, Price, T., additional, Cervantes, A., additional, Sobrero, A., additional, Ducreux, M., additional, Hotko, Y., additional, André, T., additional, Chan, E., additional, Lordick, F., additional, Punt, C., additional, Strickland, A., additional, Wilson, G., additional, Ciuleanu, T., additional, Roman, L., additional, Van Cutsem, E., additional, Yu, H., additional, Jung, A.S., additional, Sidhu, R., additional, and Patterson, S., additional

Published
2014
Full Text
View/download PDF

234. [Percutaneous radiofrequency ablation of hepatic metastases. Preliminary experience]

Author

De Baere T, Elias D, Ducreux M, Clarisse Dromain, Kuach V, Gamal El Din M, Sobotka A, Lasser P, and Roche A

Subjects
Adult, Aged, 80 and over, Male, Liver Neoplasms, Catheter Ablation, Humans, Female, Middle Aged, Aged, Retrospective Studies
Abstract

To evaluate the efficiency of percutaneous radiofrequency ablation in the treatment of liver metastases.Eighteen patients with 31 liver metastases, mainly from colorectal cancer, 10 - 35 mm in diameter (m = 23), underwent 26 courses of percutaneous radiofrequency ablation. Fifteen patients had previously undergone hepatectomy, and 3 patients had contra-indications to surgery. Imaging guidance was ultrasound in 21 patients, CT in 4 (tumors not seen with ultrasound), and both in 1. A generator working at 450 KHz with a maximum output power of 150 W was used to treat each lesion for 18 - 20 min. Treatment was monitored with real time ultrasound.Among the 12 patients followed more than 3 months, only one of the 24 treated lesions recurred after a mean follow up of 259 ¿ 109 days. Liver disease was controlled in 8 of the 12 patients after 90 - 509 days (m = 306). Among these 8 patients, 3 were tumor free after 559, 378 and 90 days, respectively; 2 died tumor free of non-tumoral disease (pulmonary embolism, digestive bleeding); 3 developed lung metastases treated with chemotherapy (n = 2) or surgery (n = 1). Three of the 12 patients had widespread hepatic tumor occurrence, and one patient died of these metastases. Six patients experienced mild skin burns, but no major complication was observed.Radiofrequency ablation of hepatic metastases appears safe and promising in this preliminary experience. Further investigation is needed.

Published
2000

236. [What are the real indications for hepatectomies in metastases of colorectal origin?]

Author

Elias D, Ducreux M, Rougier P, Jc, Sabourin, Cavalcanti A, Bonvalot S, Debaene B, Antoun S, Jean-Pierre PIGNON, and Lasser P

Subjects
Adult, Male, Analysis of Variance, Adolescent, Contraindications, Patient Selection, Liver Neoplasms, Palliative Care, Middle Aged, Prognosis, Disease-Free Survival, Hepatectomy, Humans, Female, Hospital Mortality, Prospective Studies, Colorectal Neoplasms, Aged, Neoplasm Staging
Abstract

To ascertain the real impact of classical contraindications (relative or absolute according to various authors) represented by: a high number of liver metastases (LM), the presence of associated extra-hepatic localizations (EHL), and a surgical margin less than 10 mm.A prospective study was conducted in 269 consecutive hepatectomized patients. Inclusion criteria were only the resection of all tumoral tissue, and lack of major operative risk. Fifty-nine patients had at least 4 LM, 62 had an associated EHL, and 187 had a surgical margin10 mm. Altogether, 83% of the patients did not match the classical selection criteria. Sixty-two parameters were registered. A uni- and multivariate study of prognostic factors was performed.Although 18% of the resections were palliative (R1 or R2 according to the UICC classification), and the hospital mortality was 3.3% (2.2% during the first postoperative month), global and disease-free 5-year survival rates were 34.4% and 23.3%, respectively. The number of LM had no prognostic implication. A surgical margin9 mm improved significantly the prognosis. Between 0 and 9 mm, it had no important prognostic impact if the cut surface was histologically disease-free. A margin10 mm was greatly associated with a high number of LM, a bilateral localization of LM, and extended hepatectomy. Among the EHL, only those discovered during laparotomy had a significant adverse impact on prognosis.Fundamental principles of the indications of hepatectomy for colorectal LM are to resect all the lesions and to avoid major operative risk. In complex cases, the most frequent, these principles can only be completely followed in a specialized center.

Published
1999

237. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Author

Peeters, M., Price, T.J., Cervantes, A., Sobrero, A.F., Ducreux, M., Hotko, Y., Andre, T., Chan, E., Lordick, F., Punt, C.J.A., Strickland, A.H., Wilson, G., Ciuleanu, T.E., Roman, L., Cutsem, E. van, Tzekova, V., Collins, S., Oliner, K.S., Rong, A., Gansert, J., Peeters, M., Price, T.J., Cervantes, A., Sobrero, A.F., Ducreux, M., Hotko, Y., Andre, T., Chan, E., Lordick, F., Punt, C.J.A., Strickland, A.H., Wilson, G., Ciuleanu, T.E., Roman, L., Cutsem, E. van, Tzekova, V., Collins, S., Oliner, K.S., Rong, A., and Gansert, J.

Abstract

Item does not contain fulltext, PURPOSE: Panitumumab is a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory metastatic colorectal cancer (mCRC). This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone after failure of initial treatment for mCRC by tumor KRAS status. PATIENTS AND METHODS: Patients with mCRC, one prior chemotherapy regimen for mCRC, Eastern Cooperative Oncology Group performance status 0 to 2, and available tumor tissue for biomarker testing were randomly assigned 1:1 to panitumumab 6.0 mg/kg plus FOLFIRI versus FOLFIRI every 2 weeks. The coprimary end points of PFS and overall survival (OS) were independently tested and prospectively analyzed by KRAS status. RESULTS: From June 2006 to March 2008, 1,186 patients were randomly assigned 1:1 and received treatment. KRAS status was available for 91% of patients: 597 (55%) with wild-type (WT) KRAS tumors, and 486 (45%) with mutant (MT) KRAS tumors. In the WT KRAS subpopulation, when panitumumab was added to chemotherapy, a significant improvement in PFS was observed (hazard ratio [HR] = 0.73; 95% CI, 0.59 to 0.90; P = .004); median PFS was 5.9 months for panitumumab-FOLFIRI versus 3.9 months for FOLFIRI. A nonsignificant trend toward increased OS was observed; median OS was 14.5 months versus 12.5 months, respectively (HR = 0.85, 95% CI, 0.70 to 1.04; P = .12); response rate was improved to 35% versus 10% with the addition of panitumumab. In patients with MT KRAS, there was no difference in efficacy. Adverse event rates were generally comparable across arms with the exception of known toxicities associated with anti-EGFR therapy. CONCLUSION: Panitumumab plus FOLFIRI significantly improved PFS and is well-tolerated as second-line treatment in patients with WT KRAS mCRC.

Published
2010

238. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

Author

Ducreux, M. (M.)

Subjects
Área de Medicina Clínica y Epidemiología, Hepatocellular carcinoma, Liver transplantation, Chemoembolisation, Immunotherapy, Radioembolisation
Abstract

This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.

Published
2023

240. Fréquence de survenue des évènements indésirables sévères (EIS) modifiant de façon définitive la séquence thérapeutique des patients atteints de tumeurs neuroendocrines pancréatiques bien différenciées (pTNEBD) métastatiques non résécables

Author

Berdelou, A., primary, Malka, D., additional, Leboulleux, S., additional, Boige, V., additional, Chougnet, C., additional, Burtin, P., additional, De Baere, T., additional, Scoazec, J.Y., additional, Caramella, C., additional, Schlumberger, M., additional, Ducreux, M., additional, and Baudin, E., additional

Published
2013
Full Text
View/download PDF

244. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)

Author

Ducreux, M., primary, Adenis, A., additional, Pignon, J.-P., additional, François, E., additional, Chauffert, B., additional, Ichanté, J.L., additional, Boucher, E., additional, Ychou, M., additional, Pierga, J.-Y., additional, Montoto-Grillot, C., additional, and Conroy, T., additional

Published
2013
Full Text
View/download PDF

245. Tumeurs neuroendocrines du pancréas : diagnostic, caractérisation clinique, pronostic et traitement

Author

Baudin, E., primary, Goere, D., additional, Caramella, C., additional, De Baere, T., additional, Deschamps, F., additional, Duvillard, P., additional, Malka, D., additional, Caron, O., additional, Chougnet, C., additional, Young, J., additional, Deandréis, D., additional, Leboulleux, S., additional, Dumont, F., additional, Lumbroso, J., additional, Burtin, P., additional, Boige, V., additional, Chanson, P., additional, Sclumberger, M., additional, Elias, D., additional, Scoazec, J.-Y., additional, and Ducreux, M., additional

Published
2013
Full Text
View/download PDF

246. Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: Results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601

Author

Ferrand, F., primary, Malka, D., additional, Bourredjem, A., additional, Allonier, C., additional, Bouché, O., additional, Louafi, S., additional, Boige, V., additional, Mousseau, M., additional, Raoul, J.L., additional, Bedenne, L., additional, Leduc, B., additional, Deguiral, P., additional, Faron, M., additional, Pignon, J.P., additional, and Ducreux, M., additional

Published
2013
Full Text
View/download PDF

247. Radiochimiothérapie préopératoire à base de 5-fluorouracile et d’oxaliplatine dans la prise en charge des cancers du rectum d’emblée métastatiques

Author

UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Van den Eynde, Marc, Malka, D, Tomasic, G, Dromain, C, Laplanche, A, Ezra, P, Deutsch, E, Rahmi, G, Hernandez, J, Boige, V, Goere, D, Lasser, P, Ducreux, M, Journées Francophones de Pathologie Digestive (JFPD), UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Van den Eynde, Marc, Malka, D, Tomasic, G, Dromain, C, Laplanche, A, Ezra, P, Deutsch, E, Rahmi, G, Hernandez, J, Boige, V, Goere, D, Lasser, P, Ducreux, M, and Journées Francophones de Pathologie Digestive (JFPD)

Published
2007

248. The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona.

Author

Van Laethem, J.-L., Carneiro, F., Ducreux, M., Messman, H., Lordick, F., Ilson, D.H., Allum, W.H., Haustermans, K., Lepage, C., Matysiak-Budnik, T., Cats, A., Schmiegel, W., Cervantes, A., Van Cutsem, E., Rougier, Ph., and Seufferlein, Th.

Abstract

Background and scope The management of GOJ cancers remains controversial and may vary between countries. Evidence-based attitudes and guidelines are not easy to elaborate since most of the trials and studies reported mixed cases of oesophageal (both adenocarcinoma and squamous cell tumours), GOJ and gastric cancers. The aim of this expert discussion and position paper is to elaborate practical recommendations that integrate evidence-reported literature and experience-based attitude covering all clinical aspects of GOJ cancer across different specialities and countries in Europe. Methodology Opinion leaders, selected on scientific merit were asked to answer to a prepared set of questions covering the approach of GOJ tumours from definition to therapeutic strategies. All answers were then discussed during a plenary session and reported here in providing a well-balanced reflection of both clinical expertise and updated evidence-based medicine. Results Definition, classification, diagnosis and staging of GOJ tumours were updated and debated. Therapeutic aspects including endoscopic therapy, surgical management, both multimodal curative and palliative management were also reviewed for proposing practical and consensual positions and recommendations whenever possible. Conclusion GOJ tumours deserve specific attention,not only for uniformising clinical management across countries but also for performing specific clinical and translational research,mainly in the curative perioperative setting. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

249. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007

Author

Van Cutsem, E., Dicato, M., Haustermans, K., Arber, N., Bosset, J.-F., Cunningham, D., De Gramont, A., Diaz-Rubio, E., Ducreux, M., Goldberg, R., Glynne-Jones, R., Haller, D., Kang, Y.-K., Kerr, D., Labianca, R., Minsky, B.D., Moore, M., Nordlinger, B., Rougier, P., Scheithauer, W., Schmoll, H.-J., Sobrero, A., Tabernero, J., Tempero, M., Van de Velde, C., and Zalcberg, J.

Published
2008
Full Text
View/download PDF

250. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.

Author

Ducreux, M., Cutsem, E. van, Laethem, J. van, Gress, T.M., Jeziorski, K., Rougier, P., Wagener, T., Anak, O., Baron, B., Nordlinger, B., Ducreux, M., Cutsem, E. van, Laethem, J. van, Gress, T.M., Jeziorski, K., Rougier, P., Wagener, T., Anak, O., Baron, B., and Nordlinger, B.

Abstract

Item does not contain fulltext, Previous small phase II trials have demonstrated that the combination of 5-fluorouracil (5FU) and cisplatin(CDDP) could have clinical activity in metastatic biliary tract cancer. This randomised phase II trial was designed to assess the activity and safety of a high-dose infusional weekly 5FU alone (HDFU) and the combination of 5FU, folinic acid (FA) and CDDP. Patients were included if they had histologically proven locally advanced or metastatic biliary tract carcinoma, World Health Organisation (WHO) performance status < or = 2, bilirubin <2 x upper normal limit, adequate haematological and renal functions and had not received prior chemotherapy, even in the adjuvant setting. Treatments: Arm A (HDFU) consisted of cycles of 5FU 3 g/m(2) intravenously (i.v.), 24 h infusion, weekly, for 6 weeks, followed by 1 week rest, every 7 weeks; Arm B (5FU+FA+CDDP) consisted of cycles of 5FU 2.0 g/m(2) i.v. with folinic acid 500 mg/m(2), 2 h-infusion, weekly, for 6 weeks, followed by 1 week rest plus cisplatin 50 mg/m(2), once every two weeks, for 6 weeks, followed by 1 week rest, every 7 weeks. From February 1997 to June 1999, 58 patients were randomised (29 in each arm). Patients had a median age of 58 years in Arm A and 62 years in Arm B, locally advanced disease was present in 21% of the patients in Arm A and 11% in Arm B. WHO performance status of 0/1/2 was noted in 48%/45%/7% of the patients in Arm A and 54%/43%/4% in Arm B. In both arms, the most common metastatic sites were the liver and peritoneum. Twenty-eight patients were eligible in each arm and one patient did not start the allocated therapy in Arm B. The median number of cycles was 2 [range 1-12] in Arm A and 2 [range 1-6] in Arm B. Responses for the eligible patients who started their allocated therapy were as follows: Complete Response (CR) 0% in Arm A, 4% in Arm B, Partial Response (PR) 7% in Arm A, 15% in Arm B resulting in an overall response rate [95% CI] of 7.1% in Arm A [0.9-23.5%] and 19% [6.3-38.1%] in

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results